Trinity Capital Provides $30M Growth Capital to Elucent Medical
- Editor
- Jan 27
- 1 min read
What's Happening: Trinity Capital Inc., a leading alternative asset manager, has committed $30 million in growth capital to Elucent Medical, a medical technology company specializing in guided surgical technologies. This investment will support Elucent's efforts to scale operations and accelerate innovation and commercialization of its EnVisio® System, which uses In-Body Spatial Intelligence™ to enhance surgical precision.
The Key Moves:
Trinity Capital commits $30 million in growth capital to Elucent Medical.
Funding will support Elucent's scaling of operations and commercialization efforts.
Investment follows Elucent's $44 million Series C funding round earlier in 2024.
By The Numbers :
$30 million: Amount of growth capital committed by Trinity Capital.
$44 million: Amount raised by Elucent in Series C funding earlier in 2024.
3D: Dimension of surgical awareness provided by Elucent's EnVisio® System.
Key Quotes:
"Elucent is disrupting the field of surgical guidance with its cutting-edge technology," - Lauren Cosentino, Managing Director, Life Sciences at Trinity Capital.
"We are in scale mode and are excited to partner with Trinity Capital," - Jason Pesterfield, CEO at Elucent.
"Trinity Capital's investment will be key to our continued acceleration of our innovation and commercialization efforts." - Jason Pesterfield, CEO at Elucent.
The Bottom Line: Trinity Capital's $30 million investment in Elucent Medical represents a significant boost for the medical technology company's growth plans. This funding, coming on the heels of a substantial Series C round, positions Elucent to expand its innovative surgical guidance technology and potentially transform the field of guided surgical technologies.
Comments